CHMP recommends EU approval of Roche ’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer

Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) plus chemotherapy (Abraxane®; nab-paclitaxel) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose t umours have PD-L1 expression (≥ 1%) and who have not received prior chemotherapy for metastatic disease.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: Available online 15 August 2019Source: Carbohydrate PolymersAuthor(s): Yaping Wang, Junmin Qian, Ming Yang, Weijun Xu, Jinlei Wang, Guanghui Hou, Lijie Ji, Aili SuoAbstractCombination chemotherapy has attracted more and more attention in the field of anticancer treatment. Herein, a synergetic targeted combination chemotherapy of doxorubicin (DOX) and cisplatin in breast cancer was realized by HER2 antibody-decorated nanoparticles assembled from aldehyde hyaluronic acid (AHA) and hydroxyethyl chitosan (HECS). Cisplatin and DOX were successively conjugated onto AHA through chelation and Schiff’s base ...
Source: Carbohydrate Polymers - Category: Biomedical Science Source Type: research
' The juice is worth the squeeze,'say experts, who warn against reducing the dose of adjuvant chemotherapy because it may lower survival.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Background Cancer patients often have other noncancer medical conditions. Presence of comorbidities negatively affects cancer survival. Objective The aim of this study was to investigate comorbidity, risk factors for comorbidity, and how comorbidity was associated with symptoms and quality of life in patients being treated for breast cancer. Methods One hundred and one breast cancer chemotherapy outpatients completed this study. Comorbid conditions, weight, height, and smoking status were identified by chart review. Symptoms and quality of life were self-reported using psychometrically sound instruments. Log-linear...
Source: Cancer Nursing - Category: Nursing Tags: ARTICLES Source Type: research
AbstractBiosimilar filgrastim (Sandoz) was approved in Europe in 2009 and, in 2015, was the first biosimilar approved in the USA. These authorizations were based on the “totality of evidence” concept, an approach that considers data from structural and functional characterization and comparability analysis and non-clinical and clinical studies. For biosimilar filgrastim, phase III confirmatory clinical studies were performed in the most sensitive population, pa tients with breast cancer undergoing myelosuppressive chemotherapy. In Europe and the USA, approval was granted for all indications of the reference bio...
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
Background: Persistent hair disorders resulting from cytotoxic or endocrine agents used in early stages of breast cancer such as alopecia, hirsutism, and madarosis develop in 4-35% of patients, however their impact on quality of life (QoL) has not been reported. The CHANCE study is a prospective, longitudinal study of chemotherapy- and endocrine therapy-induced hair, skin, and nail changes in women with nonmetastatic breast cancer. This preliminary analysis intends to evaluate the impact of permanent hair sequelae of adjuvant breast cancer therapies on patients ’ QoL.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Researchers looked at the time between receiving a diagnosis and beginning chemotherapy to see if a delay in treatment impacted the overall survival in   patients with breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Abstract PURPOSE: To evaluate the use of individualized piano instruction (IPI) for improving cognition among breast cancer survivors. PARTICIPANTS & SETTING: Six participants were included in an eight-week piano program with three data collection time points at baseline, midpoint, and postintervention. Participants were recruited from the breast cancer clinic of a university cancer center in South Florida. METHODOLOGIC APPROACH: Neurocognitive, psychosocial, and self-report assessments were conducted to determine potential benefits and program feasibility, including the NIH Toolbox® Cognition Ba...
Source: Oncology Nursing Forum - Category: Nursing Authors: Tags: Oncol Nurs Forum Source Type: research
Abstract PROBLEM IDENTIFICATION: This review identifies specific cardiotoxicity related to anthracycline chemotherapy, specific risk factors related to increased anthracycline chemotherapy-induced cardiotoxicity, and underlying mechanisms of action of anthracycline chemotherapy-induced cardiotoxicity. LITERATURE SEARCH: PubMed®, CINAHL®, Embase®, and Web of Science were searched in May 2018 using keywords related to heart diseases, anthracycline chemotherapy, and breast cancer. DATA EVALUATION: Data were extracted, and study quality was assessed according to PRISMA (Preferred Reporting Items ...
Source: Oncology Nursing Forum - Category: Nursing Authors: Tags: Oncol Nurs Forum Source Type: research
CONCLUSIONS: This multicentric retrospective study confirmed that sequential adjuvant therapy with anthracycline-based chemotherapy and paclitaxel for HER2 negative breast cancer is an effective and reliable regimen. PMID: 31424664 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
Abstract Metastable phenotypic state transitions in cancer cells can lead to the development of transient adaptive resistance or tolerance to chemotherapy. Here, we report that the acquisition of a phenotype marked by increased abundance of CD44 (CD44Hi) by breast cancer cells as a tolerance response to routinely used cytotoxic drugs, such as taxanes, activated a metabolic switch that conferred tolerance against unrelated standard-of-care chemotherapeutic agents, such as anthracyclines. We characterized the sequence of molecular events that connected the induced CD44Hi phenotype to increased activity of both the g...
Source: Science Signaling - Category: Biomedical Science Authors: Tags: Sci Signal Source Type: research
More News: Abraxane | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | European Medicines Agency (EMA) | Pharmaceuticals